254 related articles for article (PubMed ID: 25895822)
1. Treatment of hepatitis C in difficult-to-treat patients.
Ferenci P
Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):284-92. PubMed ID: 25895822
[TBL] [Abstract][Full Text] [Related]
2. HCV targeting of patients with cirrhosis.
Ferenci P; Kozbial K; Mandorfer M; Hofer H
J Hepatol; 2015 Oct; 63(4):1015-22. PubMed ID: 26100497
[TBL] [Abstract][Full Text] [Related]
3. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.
Wiegand J; Schiefke I; Stein K; Berg T; Kullig U; Ende K
Hamostaseologie; 2017 May; 37(2):127-130. PubMed ID: 27416915
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Chronic Hepatitis C in Special Populations.
Bunchorntavakul C; Tanwandee T
Gastroenterol Clin North Am; 2015 Dec; 44(4):883-900. PubMed ID: 26600226
[TBL] [Abstract][Full Text] [Related]
5. Direct acting antiviral therapy after liver transplantation.
Kwo PY
Curr Opin Gastroenterol; 2016 May; 32(3):152-8. PubMed ID: 27023161
[TBL] [Abstract][Full Text] [Related]
6. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
10. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
[TBL] [Abstract][Full Text] [Related]
11. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
14. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Deterding K; Höner Zu Siederdissen C; Port K; Solbach P; Sollik L; Kirschner J; Mix C; Cornberg J; Worzala D; Mix H; Manns MP; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2015 Oct; 42(7):889-901. PubMed ID: 26250762
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
[TBL] [Abstract][Full Text] [Related]
16. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
Bunchorntavakul C; Reddy KR
J Viral Hepat; 2016 Jun; 23(6):408-18. PubMed ID: 27018088
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
18. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
Kwo PY; Badshah MB
Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hepatitis C].
Schneider MD; Kronenberger B; Zeuzem S; Sarrazin C
Internist (Berl); 2015 Apr; 56(4):391-405. PubMed ID: 25762008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]